About Allergy Drops (SLIT)

SLIT is a drug used to treat allergies. It was developed by Merck & Co., Inc. (now known as Pfizer Inc.) and approved by the U.S. Food and Drug Administration (FDA) in 2008 for the treatment of atopic dermatitis, asthma, food allergies, rhinitis, contact urticaria, and other allergic conditions such as hay fever or insect bites. SLIT is available in two forms: a liquid form and a tablet form. The liquid version contains the active ingredient called allergen-specific IgE (ASI), which binds to specific allergens on the skin and triggers immune system cells to produce antibodies against them. The tablet version contains the same ASI but is absorbed through the stomach lining into the bloodstream where it works like a vaccine. There are many different types of ASI, each with its own mechanism of action. Some ASIs work quickly while others take longer to have their full effect. Each type of ASI has advantages and disadvantages. The most common side effects include nausea, vomiting, diarrhea, abdominal pain, headache, dizziness and fatigue. Other side effects may occur if the patient does not follow the instructions carefully or takes too much of the medication. Side effects can be prevented by taking only enough to get the desired result without exceeding recommended doses or by stopping use of the product immediately when symptoms begin occurring. SLIT is not recommended for children under two years old. Especially for people with severe or dangerous symptoms, SLIT is a good alternative to conventional medication or other forms of immunotherapy. About Allergy Drops (SLIT) apparently requires very little care after the first days or weeks of treatment, unlike subcutaneous immunotherapy (SCIT), and is a suitable option for children and adults who are too busy to take daily medications or have to carry them on their person. .

Sources & references used in this article:

Sublingual‐swallow immunotherapy (SLIT) with a standardized five‐grass‐pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis by A Pradalier, D Basset, P Couturier, A Claudel… – Allergy, 1999 – Wiley Online Library

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison by D Di Bona, A Plaia, MS Leto-Barone, S La Piana… – Journal of allergy and …, 2012 – Elsevier

EAACI Guidelines on Allergen Immunotherapy: House dust mite‐driven allergic asthma by I Agache, S Lau, CA Akdis, S Smolinska, M Bonini… – Allergy, 2019 – Wiley Online Library

… , placebo‐controlled multi‐centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass … by C Rolinck‐Werninghaus, H Wolf, C Liebke, JC Baars… – Allergy, 2004 – Wiley Online Library

Effects on inflammation parameters of a double‐blind, placebo controlled one‐year course of SLIT in children monosensitized to mites by F Marcucci, L Sensi, F Frati, R Bernardini… – Allergy, 2003 – Wiley Online Library

Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides Farinae Drops by LF Cao, Q Lu, HL Gu, YP Chen, Y Zhang… – Zhonghua er ke za …, 2007 – europepmc.org

Patient initiation and persistence with allergen immunotherapy by R Anolik, AM Schwartz, S Sajjan… – Annals of Allergy, Asthma …, 2014 – Elsevier